title: [Current chemotherapy of locally advanced or metastatic bladder tumors].
abstract: Standard chemotherapy of transitional cell carcinoma of the bladder is actually the combination of cisplatine, methothrexate, vinblastine and doxorubicine (MVAC). Although a high response rate, long term survival are rarely observed. More effective agents without toxicity are necessary. Several agents have demonstrated activity alone or in combinations. Combinations regimens use, paclitaxel, gemcitabine and Gallium nitrate, who prove activity alone or in combination with cisplatine or carboplatine, with a response rate of 40 to 70% in patient with visceral localisations. The optimal regimen is not yet determined.
authors.affiliation: Service the radiothérapie et d'oncologie médicale, Hôpital d'instruction des armées du Val-de-Grâce, Paris.
authors.forename: L M
authors.initials: LM
authors.lastname: Dourthe
authors.forename: B
authors.initials: B
authors.lastname: Ceccaldi
authors.forename: R
authors.initials: R
authors.lastname: Fournier
authors.forename: A
authors.initials: A
authors.lastname: Houlgatte
authors.forename: J
authors.initials: J
authors.lastname: Merrer
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents